Real-world safety study of posaconazole oral suspension in children under 13 years of age
In the present study,we aimed to investigate the safety of posaconazole oral suspension in children under 13 years of age.A retrospective analysis was conducted on six cases of pediatric patients with acute lymphocytic leukemia who received prophylactic or sequential treatment with posaconazole oral suspension.Among the six patients(four boys and two girls)with an average age of(8.67±1.86)years,one child developed bilateral lower limb edema after 7 d of posaconazole oral suspension,and two children experienced elevated levels of liver enzymes during the course of treatment.In conclusion,common adverse reactions of posaconazole included liver damage and gastrointestinal symptoms.However,reports of lower limb edema in patients are rare.Further studies with larger sample sizes are needed to evaluate the safety of posaconazole oral suspension in children under 13 years of age.
NETL
NSTL
万方数据
